RxDoctor Payments Data

William Hooper, MD

Pulmonary Disease · Encinitas, CANPI 1720052988

Payments from drug & device makers

$6,963in general payments, 2019–2025

Across 350 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • GSK$1K
  • AstraZeneca$638
  • Philips North America LLC$431
  • Sanofi$333
  • Actelion Pharmaceuticals US, Inc.$301
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,963 in reported general payments places this provider in the 70th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$65,830
Medicare patients
263
Services billed
562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate20$253,866
EliquisApixaban73$66,371
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$63,545
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr59$37,016
XareltoRivaroxaban15$22,479
Incruse ElliptaUmeclidinium Bromide38$21,164
Breo ElliptaFluticasone/Vilanterol21$13,714
Serevent DiskusSalmeterol Xinafoate12$9,985
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$8,659
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$4,540
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$4,022
Wixela InhubFluticasone Propion/Salmeterol52$4,017
Albuterol Sulfate HfaAlbuterol Sulfate77$2,267
Theophylline ErTheophylline Anhydrous19$1,517
Ipratropium Bromide20$991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$1,310$253,86620 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$1,120$135,439176 claims
PfizerEliquis$44$66,37173 claims
Johnson & JohnsonXarelto$36$22,47915 claims
AstraZenecaBreztri Aerosphere$638$8,65915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Encinitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →